EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SGLT2 inhibition, venous thrombolism, and death due to cardiac causes: a mediation Mendelian randomization study

Lili Shi, Xiupan Wei, Jinlan Luo, Ling Tu

Frontiers in Cardiovascular Medicine · 13.05.2024 · 11

DOI: 10.3389/fcvm.2024.1339094 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 13.05.2024. Verfasst von Lili Shi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the causal role of venous thrombolism mediating sodium-glucose cotransporter 2 (SGLT2) inhibition in death due to cardiac causes using Mendelian randomization (MR).

Methods

A two-sample two-step MR was used to determine (1) the causal effects of SGLT2 inhibition on death due to cardiac causes; (2) the causal effects of venous thrombolism on death due to cardiac causes; and (3) the mediation effects of venous thrombolism. Genetic proxies for SGLT2 inhibition were identified as variants in the SLC5A2 gene that were associated with both levels of gene expression and hemoglobin A1c. Additionally, employing MR to investigate the causal association between SGLT2 inhibition and cardiac arrest as well as coronary heart disease (CHD).

Results

SGLT2 inhibition was associated with a lower risk of death due to cardiac causes (odds ratio [OR] = 0.983, [95% CI = 0.972, 0.993], P = 0.0016). Venous thrombolism was associated with death due to cardiac causes ([OR] = 1.031, [95% CI = 1.005, 1.057], P = 0.0199). Mediation analysis showed evidence of indirect effect of SGLT2 inhibition on death due to cardiac causes through venous thrombolism [β = −0.0015, (95% CI = −0.0032 −0.0002), P = 0.042], with a mediated proportion of 8.9% (95% CI = 1.2%, 18.7%) of the total. Furthermore, SGLT2 inhibition was linked to a lower risk of cardiac arrest ([OR] = 0.097, [95% CI = 0.013, 0.742], P = 0.025). SGLT2 inhibition was linked to a lower risk of CHD ([OR] = 0.957, [95% CI = 0.932, 0.982], P = 0.0009).

Conclusions

Our study identified the causal roles of SGLT2 inhibition in venous thrombolism. SGLT2 inhibition may influence death due to cardiac causes through venous thrombolism. Additionally, SGLT2 inhibition was associated with reduced risk of cardiac arrest and CHD.

Schlagwörter

Stichwörter der Autor:innen

Mendelian randomizationSGLT2 inhibitioncardiac eventsmortality ratesvenous thrombolism

Autor:innen und Institutionen

  • Department of Geriatric Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, China.
  • Department of Rehabilitation Medicine, Zhongda Hospital, Southeast University, Nanjing, China.

Zitieren

APA

Shi, L., Wei, X., Luo, J., & Tu, L. (2024). SGLT2 inhibition, venous thrombolism, and death due to cardiac causes: a mediation Mendelian randomization study. Frontiers in Cardiovascular Medicine, 11. https://doi.org/10.3389/fcvm.2024.1339094

Vancouver

Shi L, Wei X, Luo J, Tu L. SGLT2 inhibition, venous thrombolism, and death due to cardiac causes: a mediation Mendelian randomization study. Frontiers in Cardiovascular Medicine. 2024;11. doi:10.3389/fcvm.2024.1339094

BibTeX
@article{Shi2024,
  author = {Shi, Lili and Wei, Xiupan and Luo, Jinlan and Tu, Ling},
  title = {SGLT2 inhibition, venous thrombolism, and death due to cardiac causes: a mediation Mendelian randomization study},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2024},
  volume = {11},
  doi = {10.3389/fcvm.2024.1339094}
}
Kostenlos starten →